Session 3: Bone Sarcomas

Moderator(s)

• 

  Claudia Valverde Morales, MD, PhD

  Dr
  Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d´Hebrón Institute of Oncology
  Barcelona, Catalonia, Spain
• 

  Ravin Ratan, MD, MEd

  Associate Professor
  University of Texas, MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Division of Cancer Medicine
  Houston, Texas, United States

Presentations:

• 1:45 PM – 3:15 PM PST

  SACRAL CHORDOMA: A RANDOMIZED AND OBSERVATIONAL STUDY ON SURGERY VS DEFINITIVE RADIOTHERAPY IN PRIMARY LOCALIZED DISEASE (SACRO): INTERIM ANALYSIS
  

  Author: Stefano Radaelli, MD (he/him/his) – Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  Co-Author: Maria Rosaria Fiore, M.D. – Fondazione CNAO - Centro Nazionale di Adroterapia Oncologica, Pavia, Italy

  Co-Author: Maria Grazia Petrongari, M.D. – IRCCS - Istituto Nazionale Tumori Regina Elena,Rome , Italy

  Co-Author: Alessandro Gasbarrini, M.D. – IRCCS Istituto Ortopedico Rizzoli; Bologna, Italy

  Co-Author: Øyvind Bruland, M.D. – slo University Hospital - Norwegian Radium Hospital, Oslo, Norway

  Co-Author: Maria Pilar Sancho Marquez, MD – Hospital Universitario Virgen del Rocio

  Co-Author: Jendrik Hardes, M.D. – Klinik für Tumororthopädie - Universitätsklinikum Essen, Essen, Germany

  Co-Author: Susanne Scheipl, MD, PhD (she/her/hers) – Univ. Klinik für Orthopädie und Traumatologie Medizinische Universität Graz, Graz, Austria

  Co-Author: Beate Timmermann, M.D. – Westdeutsches Protonentherapiezentrum Essen (WPE), Essen, Germany

  Co-Author: Toru Akiyama, M.D. – Saitama Medical Center, Saitama, Japan

  Co-Author: Ferdinando CM Cananzi, MD – IRCCS Humanitas Research Hospital

  Co-Author: Davide Maria Donati, M.D. – IRCCS Istituto Ortopedico Rizzoli; Bologna, Italy

  Co-Author: Lorenzo Andreani, M.D. – Universita' di Pisa - Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

  Co-Author: Josè Manuel Asencio, M.D. – Hospital Universitario Gregorio Marañón, Madrid, Spain

  Co-Author: Ramona Verges Capdevila, M.D, PhD – Hospital Val D’Hebron, Barcelona, Spain.

  Co-Author: Alessandro Luzzati, M.D. – IRCCS, Istiuto Ortopedico Galeazzi

  Co-Author: Viviana Appolloni, PhD (she/her/hers) – Italian Sarcoma Group ETS, Italy

  Co-Author: Gianluca Ignazzi (he/him/his) – Italian Sarcoma Group ETS, Italy

  Co-Author: Daniela Salvatore, PhD – Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

  Co-Author: Matteo Carotenuto – Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  Co-Author: Rosalba Miceli, PhD (she/her/hers) – Fondazione IRCCS Istituto Nazionale dei Tumori

  Co-Author: Silvia Stacchiotti, MD – Fondazione IRCCS Istituto Nazionale dei Tumori

  Co-Author: Piero Fossati, M.D. – MedAustron Ion Therapy Centre, Graz, Austria

  Co-Author: Alessandro Gronchi, MD, FSSO (he/him/his) – Fondazione IRCCS Istituto Nazionale dei Tumori
• 1:45 PM – 3:15 PM PST

  INTEREST OF A SEQUENTIAL MULTIMODAL APPROACH FOR THE TREATMENT OF NEWLY DIAGNOSED PATIENTS WITH MULTIMETASTATIC EWING SARCOMA: RESULTS OF THE FRENCH PROSPECTIVE COMBINAIR3 PHASE II TRIAL
  

  Author: Nadège Corradini, MD – IHOPE- Leon Berard Center

  Co-Author: Camille Cordero, MD – Institut Curie

  Co-Author: Sylvain Dureau, Pharma Biostatistician – Institut Curie

  Co-Author: Nina Jehanoo, MD – Institut Curie

  Co-Author: Gaelle Pierron, PhD – Institut Curie

  Co-Author: Nathalie Gaspar, MD, PhD – Gustave Roussy Cancer Campus

  Co-Author: Thibaud Valentin, MD – IUCT-Oncopole

  Co-Author: Gabriel Revon-Rivière, MD – APHM

  Co-Author: Cyril Lervat, MD – Centre Oscar Lambret

  Co-Author: Jamie Probert, MD – CHU Hôpital sud

  Co-Author: Natacha Entz-Werlé, MD, PhD (she/her/hers) – UMR7021 CNRS -Laboratory of Bioimaging and Pathologies

  Co-Author: Ludovic Mansuy, MD – CHRU Nancy - Brabois

  Co-Author: Dominique Plantaz, Pr – CHU Grenoble

  Co-Author: Maria Rios, MD – Institut de Cancérologie de Lorraine

  Co-Author: Laure Saumet, MD – CHU Montpellier

  Co-Author: Cécile Verite, MD – CHU Bordeaux

  Co-Author: Marie-Pierre Castex, MD – CHU Toulouse

  Co-Author: Estelle Thebaut, MD – CHU Nantes

  Co-Author: Mehdi Brahmi, MD, PhD – Centre Leon Berard

  Co-Author: Didier Surdez, PhD, PharmD – Balgrist University Hospital

  Co-Author: Line Claude, MD – Centre Léon Bérard

  Co-Author: Anne-Sophie Plissonnier, CRA – Institut Curie

  Co-Author: Marie-Emmanuelle Legrier, PhD – Institut Curie

  Co-Author: Perrine Marec-Berard, MD – Centre Léon Bérard / iHOPe

  Co-Author: François Gouin, MD, PhD – Centre Léon Bérard

  Co-Author: Pablo Berlanga, MD, PhD – Gustave Roussy Cancer Campus

  Co-Author: Thibaut Cassou-Mounat, MD – IUCT - oncopole

  Co-Author: Lieke Mous, PhD – Balgrist University Hospital

  Co-Author: Stelly Ballet, Engineer M.Sc – Institut Curie

  Co-Author: Valérie Laurence, MD – Institut Curie
• 1:45 PM – 3:15 PM PST

  PRE-TREATMENT CTDNA BURDEN IS PROGNOSTIC AMONG PATIENTS WITH LOCALIZED EWING SARCOMA: A REPORT FROM THE LEOPARD STUDY
  

  Author: David Shulman, MD – Dana-Farber Cancer Institute

  Co-Author: Kelly Klega, MS – Dana-Farber Cancer Institute

  Co-Author: Nan Chen, MS – Dana-Farber/Boston Children's Cancer and Blood Disorders Center

  Co-Author: Elliot Gohn, BS – Dana-Farber Cancer Institute

  Co-Author: Sarah Sexton, BS – Dana-Farber Cancer Institute

  Co-Author: Donovan Henry, BS – Dana-Farber Cancer Institute

  Co-Author: Edwin Choy, MD PhD (he/him/his) – Massachusetts General Hospital

  Co-Author: William Cash, MD – Children's Hospital of Atlanta

  Co-Author: Christopher Kuo, M.D (he/him/his) – Children's Hospital Los Angeles

  Co-Author: Kris Ann Schultz, MD – Children's Minnesota Hematology Oncology

  Co-Author: Leo Mascarenhas, MD, MS – Cedars-Sinai Medical Center, California, CA, USA

  Co-Author: Rochelle Bagatell, MD – Children's Hospital of Philadelphia

  Co-Author: Brian Turpin, DO – Cincinnati Children's

  Co-Author: Bhuvana Setty, MD – Nationwide Children's Hospital

  Co-Author: Bradley Denardo, MD – Hasbro Children's Hospital

  Co-Author: Douglas S. Hawkins, MD – Seattle Children’s Hospital, University of Washington

  Co-Author: Michael Bishop, MD – St. Jude Children's Research Hospital

  Co-Author: Avanthi Shah, MD – UT Southwestern Medical Center

  Co-Author: Luke Maese, DO – University of Utah

  Co-Author: Wendy London, PhD – Dana-Farber/Boston Children's Cancer and Blood Disorders Center

  Co-Author: Steven G. DuBois, MD, MS – Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, MA, USA

  Co-Author: Brian Crompton, MD – Department of Pediatrics, Dana-Farber / Boston Children’s Cancer and Blood Disorders Center Harvard Medical School
• 1:45 PM – 3:15 PM PST

  IS THERE A ROLE FOR MIFAMURTIDE IN NONMETASTATIC EXTREMITY HIGH-GRADE OSTEOSARCOMA PATIENTS? RESULTS OF PROSPECTIVE ITALIAN SARCOMA GROUP (ISG/OS-2) AND SPANISH SARCOMA GROUP (GEIS-33) TRIALS
  

  Author: Emanuela Palmerini, MD, PhD – IRCCS Istituto Ortopedico Rizzoli

  Co-Author: Cristina Meazza, MD – Pediatric Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori,

  Co-Author: Angela Tamburini, MD – AOU Meyer IRCCS

  Co-Author: Catalina Márquez-Vega, MD – ediatric Oncology Unit, Hospital Infantil Universitario Virgen del Rocío

  Co-Author: Gianni Bisogno, MD, Prof – Univeristy of Padua

  Co-Author: Franca Fagioli, MD, Prof – University of Turin

  Co-Author: Virginia Ferraresi, MD – IRCCS Istituto Nazionale Tumori Regina Elena

  Co-Author: Giuseppe Maria Milano, MD – 8. Division of Pediatric Hematology and Oncology, Gene and Cellular Therapy, IRCCS Ospedale Pediatrico Bambino Gesù

  Co-Author: Luca Coccoli, MD – Stem Cell Transplantation, S. Chiara Hospital, AOUP, Pisa,

  Co-Author: Alba Rubio Simon, MD – Hospital Infantil Universitario Niño Jesús

  Co-Author: Oscar Gallego, MD – Hospital de la Santa Creu i Sant Pau

  Co-Author: María Esther Llinares Riestra, MD – Pediatric Oncology Unit, Hospital Infantil Universitario Clinico Virgen de la Arrixca

  Co-Author: Carla Manzitti, MD – IRCCS Istituto Giannina Gaslini

  Co-Author: Jaume Mora, MD, PhD – Hospital Sant Joan de Déu

  Co-Author: Mª Ángeles Vaz-Salgado, MD, Prof – Hospital Universitario Ramón y Cajal, Irycis

  Co-Author: Roberto Luksch, MD – 2. S.C. Oncologia Pediatrica, Fondazione IRCCS Istituto Nazionale dei Tumori

  Co-Author: Cristina Mata, MD – Hospital General Universitario Gregorio Marañón

  Co-Author: Michela Pierini, PhD – Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy

  Co-Author: Eisa Carretta, Bsc – Department of Programming and Monitoring, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

  Co-Author: Marilena Cesari, MD – IRCCS Istituto Ortopedico Rizzoli

  Co-Author: Anna Paioli, MD – IRCCS Istituto Ortopedico Rizzoli

  Co-Author: Andrea Marrari, MD – IRCCS Istituto Ortopedico Rizzoli

  Co-Author: Massimo Serra (he/him/his) – IRCCS Istituto Ortopedico Rizzoli

  Co-Author: Katia Scotlandi, PhD – IRCCS Istituto Orthopedico Rizzoli

  Co-Author: Sebastian Dorin Asaftei, MD – Regina Margherita Children Hospital

  Co-Author: Marco Gambarotti, MD – Department of Pathology, IRCCS, Istituto Ortopedico Rizzoli

  Co-Author: Claudia Valverde, MD, PhD (she/her/hers) – Hospital Universitari Vall d’Hebron

  Co-Author: Toni Ibrahim, MD, PhD, MSc – Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS, Istituto Ortopedico Rizzoli, Bologna, Italy

  Co-Author: Javier Martín Broto, MD – Hospital Universitario Fundación Jiménez Díaz
• 1:45 PM – 3:15 PM PST

  APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE ALONE IN THE TREATMENT OF RELAPSED OR REFRACTORY OSTEOSARCOMA: A MULTICENTER RANDOMIZED CONTROLLED TRIAL
  

  Author: Lu Xie, MD (she/her/hers) – Peking University People's Hospital

  Co-Author: Jie Xu, M.D. – Peking University People’s Hospital

  Co-Author: Xin Sun, M.D. – Peking University People’s Hospital

  Co-Author: Xin Liang, M.D. – Peking University People’s Hospital

  Co-Author: Kuisheng Liu, M.D. – Peking University People’s Hospital

  Co-Author: Kunkun Sun, M.D. – Peking University People’s Hospital

  Co-Author: Yuan Li, M.D. – Peking University People’s Hospital

  Co-Author: Rong Liu, M.D. – Peking University People’s Hospital

  Co-Author: Du Wang, Ph.D. – Jiangsu Hengrui Pharmaceuticals Co, Ltd.

  Co-Author: Shurong Shao, M.SC. – Jiangsu Hengrui Pharmaceuticals Co, Ltd.

  Co-Author: Zhongjiang Chen, Ph.D. – Jiangsu Hengrui Pharmaceuticals Co, Ltd.

  Co-Author: Zheng Pang, M.M. – Jiangsu Hengrui Pharmaceuticals Co, Ltd.

  Co-Author: Guangxin Zhou, M.D. – Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University

  Co-Author: Sujia Wu, M.D. – Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University

  Co-Author: Yingqi Hua, M.D. – Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  Co-Author: Haiyan Hu, M.D. – Shanghai Jiao Tong University Affiliated Sixth People’s Hospital

  Co-Author: Yi Yang, M.D. – Peking University People’s Hospital

  Co-Author: Tao Ji, M.D. – Peking University People’s Hospital

  Co-Author: Wei Guo, M.D., Ph.D. – Peking University People’s Hospital

  Co-Author: Xiaodong Tang, MD (he/him/his) – Peking University People's Hospital
• 1:45 PM – 3:15 PM PST

  PHASE 1 RESULTS OF THE WEE1 INHIBITOR, AZENOSERTIB, IN COMBINATION WITH GEMCITABINE IN ADULT AND PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
  

  Author: Viswatej Avutu, MD (he/him/his) – Memorial Sloan Kettering Cancer Center

  Co-Author: J. Andrew Livingston, MD, MS – The University of Texas MD Anderson Cancer Center, Houston, TX, USA

  Co-Author: Noah Federman, MD – UCLA David Geffen School of Medicine

  Co-Author: Lee Cranmer, MD, PhD, FACP – University of Washington

  Co-Author: Nathalie Gaspar, MD, PhD – Gustave Roussy Cancer Campus

  Co-Author: Maud Toulmonde, MD, PhD – Institut Bergonie

  Co-Author: Joseph Pressey, MD – The University of Cincinnati

  Co-Author: Mehdi Brahmi, MD, PhD – Centre Leon Berard

  Co-Author: Andrew Poklepovic, MD – School of Medicine, Virginia Commonwealth University

  Co-Author: Qing Shi, n/a – Zentalis Pharmaceuticals

  Co-Author: Nathan M. Jameson, PhD (he/him/his) – Zentalis Pharmaceuticals

  Co-Author: Sant P. Chawla, MD, FRACP – Sarcoma Oncology Research Center

  Co-Author: William D. Tap, MD – Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College
• 1:45 PM – 3:15 PM PST

  A MULTI-CENTER PHASE II STUDY OF THE ANTI-GD2 HUMANIZED MONOCLONAL ANTIBODY NAXITAMAB IN COMBINATION WITH GM-CSF IN RECURRENT OSTEOSARCOMA.
  

  Author: Filemon S. Dela Cruz, MD (he/him/his) – Memorial Sloan Kettering Cancer Center

  Co-Author: Audrey Mauguen, PhD – Memorial Sloan Kettering Cancer Center

  Co-Author: Liela Piracha, BS – Memorial Sloan Kettering Cancer Center

  Co-Author: Charlie White, MS – Memorial Sloan Kettering Cancer Center

  Co-Author: Nicole Manino, n/a – Memorial Sloan Kettering Cancer Center

  Co-Author: Catherine Poulcallec, n/a – Memorial Sloan Kettering Cancer Center

  Co-Author: Hassan Musleh, MD – Memorial Sloan Kettering Cancer Center

  Co-Author: Fariba Navid, MD – Children's Hospital Los Angeles

  Co-Author: Jonathan B. Gill, MD – University of Texas MD Anderson Cancer Center

  Co-Author: Douglas J. Harrison, MD – University of Texas MD Anderson Cancer Center

  Co-Author: Melissa A. Burns, MD – Harvard Medical School/Dana-Farber Cancer Institute

  Co-Author: Emily K. Slotkin, MD – Memorial Sloan Kettering Cancer Center

  Co-Author: Julia Glade Bender, MD – Memorial Sloan Kettering Cancer Center

  Co-Author: Michael V. Ortiz, MD – Memorial Sloan Kettering Cancer Center

  Co-Author: Leonard H. Wexler, MD – Memorial Sloan Kettering Cancer Center

  Co-Author: Christine A. Pratilas, MD – Johns Hopkins University School of Medicine

  Co-Author: Irene Y. Cheung, ScD – Memorial Sloan Kettering Cancer Center

  Co-Author: Shakeel Modak, MD – Memorial Sloan Kettering Cancer Center

  Co-Author: Fiorella Iglesias Cardenas, MD – Memorial Sloan Kettering Cancer Center

  Co-Author: Ellen M. Basu, MD PhD – Memorial Sloan Kettering Cancer Center

  Co-Author: Alexander J. Chou, MD – Weill Cornell Medical College

  Co-Author: Stephen S. Roberts, MD – Oregon Health Sciences University

  Co-Author: Nai-Kong V. Cheung, MD PhD – Memorial Sloan Kettering Cancer Center

  Co-Author: Paul A. Meyers, MD – Memorial Sloan Kettering Cancer Center
• 1:45 PM – 3:15 PM PST

  A PHASE 1/2 TRIAL OF GEMCITABINE, DOCETAXEL, AND HYDROXYCHLOROQUINE IN ADVANCED METASTATIC OSTEOSARCOMA: FINAL RESULTS
  

  Author: J. Andrew Livingston, MD, MS – The University of Texas MD Anderson Cancer Center, Houston, TX, USA

  Co-Author: Jonathan B. Gill, MD – University of Texas MD Anderson Cancer Center

  Co-Author: Anthony P. Conley, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Neeta Somaiah, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Dejka Araujo, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Ravin Ratan, MD, MEd – University of Texas, MD Anderson Cancer Center, Department of Sarcoma Medical Oncology, Division of Cancer Medicine

  Co-Author: Vinod Ravi, MD, MBA – The University of Texas MD Anderson Cancer Center

  Co-Author: Alex Zarzour, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Robert Benjamin, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Shreyaskumar Patel, MD MS – The University of Texas MD Anderson Cancer Center

  Co-Author: Najat Daw, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Douglas J. Harrison, MD – University of Texas MD Anderson Cancer Center

  Co-Author: Richard Gorlick, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Taryn Otto, BA – The University of Texas MD Anderson Cancer Center

  Co-Author: Heather Lin, PhD – The University of Texas MD Anderson Cancer Center

  Co-Author: Wei-lien Wang, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Behrang Amini, MD PhD – The University of Texas MD Anderson Cancer Center

  Co-Author: Eugenie Kleinerman, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Nancy Gordon, MD – The University of Texas MD Anderson Cancer Center
• 1:45 PM – 3:15 PM PST

  A PHASE IB STUDY TO EVALUATE THE FEASIBILITY OF NIVOLUMAB OR NIVOLUMAB WITH AZACITIDINE IN PATIENTS WITH RECURRENT, RESECTABLE OSTEOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
  

  Author: Matthew E. Campbell, MD – University of Texas Southwestern Medical Center

  Co-Author: Brooke Fridley, PhD – Children's Mercy

  Co-Author: Vivien Yin, PhD – Moffitt Cancer Center

  Co-Author: Jessica Crimella, BSN, RN, CCRP – Moffitt Cancer Center

  Co-Author: Junmin Whiting, PhD – Moffitt Cancer Center

  Co-Author: Javier Oesterheld, MD – Carolina Medical Center, Levine Cancer Institute

  Co-Author: Joanne Lagmay, MD – Shand's Hospital for Children at the University of Florida

  Co-Author: Bhuvana Setty, MD – Nationwide Children's Hospital

  Co-Author: Scott C. Borinstein, MD, PhD – Vanderbilt University Medical Center

  Co-Author: Michael Isakoff, MD – Connecticut Children's Medical Center

  Co-Author: Thomas C. Badgett, MD, PhD – University of Kentucky

  Co-Author: Eric Sandler, MD – Nemours Children's Hospital

  Co-Author: Brian Ladle, MD, PhD – Johns Hopkins University

  Co-Author: Ajay Gupta, MD – Roswell Park Comprehensive Cancer Center

  Co-Author: Lars Wagner, MD – Duke University

  Co-Author: Matteo Trucco, MD – Cleveland Clinic

  Co-Author: Jonathan Metts, MD – Moffitt Cancer Center

  Co-Author: Damon Reed, MD – Memorial Sloan Kettering

  Co-Author: Nicolas Llosa, MD – Johns Hopkins University

  Co-Author: Mihaela Druta, MD – Moffitt Cancer Center & Research Institute

  Co-Author: Patrick Thompson, MD – University of North Carolina at Chapel Hill